130 related articles for article (PubMed ID: 35377864)
1. Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases.
Ingen-Housz-Oro S; Milpied B; Badrignans M; Carrera C; Elshot YS; Bensaid B; Segura S; Apalla Z; Markova A; Staumont-Sallé D; Marti-Marti I; Giavedoni P; Chua SL; Darrigade AS; Dezoteux F; Starace M; Torre AC; Riganti J; de Prost N; Lebrun-Vignes B; Bauvin O; Walsh S; Ortonne N; French LE; Sibaud V
Melanoma Res; 2022 Jun; 32(3):205-210. PubMed ID: 35377864
[TBL] [Abstract][Full Text] [Related]
2. Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases.
Ingen-Housz-Oro S; Milpied B; Bensaid B; Elshot Y; Brüggen MC; Starace M; Kaffenberger BH; Carrera C; Pham-Ledard A; Freites-Martinez A; Sanchez-Pena P; Lebrun-Vignes B; French LE; Sibaud V
Melanoma Res; 2023 Apr; 33(2):155-158. PubMed ID: 36749114
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
4. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
7. Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature.
Emonet C; Tétart F; Bauvin O; Cellier L; Courville P; Mignard C; Janela-Lapert R; Lefebvre A; Lachkar S; Lechevalier D; Lagarce L; Carvalho P; Tedbirt B
J Immunother; 2023 Feb-Mar 01; 46(2):59-63. PubMed ID: 36622668
[TBL] [Abstract][Full Text] [Related]
8. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
[TBL] [Abstract][Full Text] [Related]
9. Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid-A Retrospective, Monocentric Study.
Schauer F; Rafei-Shamsabadi D; Mai S; Mai Y; Izumi K; Meiss F; Kiritsi D
Front Immunol; 2022; 13():953546. PubMed ID: 35936009
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations induced by check point inhibitors in 120 melanoma patients-The European MelSkinTox study.
L'Orphelin JM; Cassecuel J; Kandolf L; Harwood CA; Tookey P; Junejo MH; Hogan S; Lebbé C; Appalla Z; Kränke TM; Pellacani G; Cerasuolo D; Dujovic B; Del Marmol V; Forschner A; Garbe C; Bataille V; Ressler JM; Sollena P; Dompmartin A; Peris K; Dreno B;
J Eur Acad Dermatol Venereol; 2023 Apr; ():. PubMed ID: 37042810
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience.
Merli M; Accorinti M; Romagnuolo M; Marzano A; Di Zenzo G; Moro F; Antiga E; Maglie R; Cozzani E; Parodi A; Gasparini G; Sollena P; De Simone C; Caproni M; Pisano L; Fattore D; Balestri R; Sena P; Vezzoli P; Teoli M; Ardigò M; Vassallo C; Michelerio A; Satta RR; Dika E; Melotti B; Ribero S; Quaglino P
Front Med (Lausanne); 2023; 10():1208418. PubMed ID: 37547602
[TBL] [Abstract][Full Text] [Related]
14. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
15. Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital.
Torres-Jiménez J; Esteban-Villarrubia J; García-Abellás P; Cortés-Salgado A; Soria-Rivas A; Gajate-Borau P; Olmedo-García ME; Corral-de la Fuente E; Lage-Alfranca Y; Gómez-Rueda A; Benito-Berlinches A; Gorospe-Sarasua L; Garrido-López P
Clin Transl Oncol; 2021 Jul; 23(7):1474-1480. PubMed ID: 33433837
[TBL] [Abstract][Full Text] [Related]
16. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
[TBL] [Abstract][Full Text] [Related]
17. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
[TBL] [Abstract][Full Text] [Related]
18. The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes.
Hashimoto H; Ito T; Ichiki T; Yamada Y; Oda Y; Furue M
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33673164
[TBL] [Abstract][Full Text] [Related]
19. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract][Full Text] [Related]
20. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis.
Versluis JM; Hendriks AM; Weppler AM; Brown LJ; de Joode K; Suijkerbuijk KPM; Zimmer L; Kapiteijn EW; Allayous C; Johnson DB; Hepner A; Mangana J; Bhave P; Jansen YJL; Trojaniello C; Atkinson V; Storey L; Lorigan P; Ascierto PA; Neyns B; Haydon A; Menzies AM; Long GV; Lebbe C; van der Veldt AAM; Carlino MS; Sandhu S; van Tinteren H; de Vries EGE; Blank CU; Jalving M
Eur J Cancer; 2021 Jul; 151():72-83. PubMed ID: 33971447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
